ImmuCell Corp Files 8-K on Financials
Ticker: ICCC · Form: 8-K · Filed: Oct 7, 2025 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
ImmuCell filed its 8-K. Standard financial update.
AI Summary
ImmuCell Corporation filed an 8-K on October 7, 2025, reporting on its financial condition and results of operations. The filing does not contain specific financial figures or operational details within the provided text, but indicates a standard reporting event for the company.
Why It Matters
This filing is a routine update for investors and regulators regarding ImmuCell's financial performance and operational status. It serves as a key disclosure point for the company's ongoing business.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting, not indicating any immediate adverse events.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Portland, Maine (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on ImmuCell Corporation's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on October 7, 2025.
What is ImmuCell Corporation's principal executive office address?
ImmuCell Corporation's principal executive office is located at 56 Evergreen Drive, Portland, Maine 04103.
What is ImmuCell Corporation's telephone number?
ImmuCell Corporation's telephone number, including area code, is 207-878-2770.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-10-07 16:06:05
Key Financial Figures
- $0.10 — ge on which registered Common Stock , $0.10 par value per share ICCC The Nasdaq
Filing Documents
- iccc20251007_8k.htm (8-K) — 32KB
- ex_867237.htm (EX-99.1) — 20KB
- 0001437749-25-030631.txt ( ) — 185KB
- iccc-20251007.xsd (EX-101.SCH) — 3KB
- iccc-20251007_def.xml (EX-101.DEF) — 11KB
- iccc-20251007_lab.xml (EX-101.LAB) — 15KB
- iccc-20251007_pre.xml (EX-101.PRE) — 11KB
- iccc20251007_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On October 7, 2025 ImmuCell Corporation (the "Company") issued a press release announcing its preliminary, unaudited product sales for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release of the Company dated October 7, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: October 7, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer Date: October 7, 2025 By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of the Company dated October 7, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3